Literature DB >> 27794575

Level of Vascular Endothelial Growth Factor in the Vitreous Fluid of Proliferative Diabetic Retinopathy Patients and Prognosis after Vitrectomy.

Yukihiko Suzuki1, Kaori Suzuki, Takashi Kudo, Tomomi Metoki, Mitsuru Nakazawa.   

Abstract

PURPOSE: The aim of this study was to evaluate the relationship between the intravitreal vascular endothelial growth factor (VEGF) level and prognosis of proliferative diabetic retinopathy (PDR).
METHODS: The study involved 136 eyes of 114 PDR patients who underwent an initial vitrectomy between 2006 and 2008. Intravitreal VEGF levels were determined using Bio-Plex® (Bio-Rad), with levels of 5,000 pg/mL or more classified as high-VEGF (45 eyes) and levels lower than 5,000 pg/mL as low-VEGF (91 eyes). Diabetic control, PDR severity, and frequency of postoperative complications were compared between the groups.
RESULTS: There was no significant difference in preoperative status between the groups. In the low-VEGF group, a reoperation was required due to postoperative complications in 2 eyes (2.2%); 1 with vitreous hemorrhage (VH) and 1 with retinal detachment (RD). In contrast, a reoperation was required in 8 eyes (17.8%) in the high-VEGF group; 3 with VH, 2 with RD, and 3 with neovascular glaucoma. The difference between the groups was significant. There was a statistically lower postoperative corrected visual acuity logMAR (6 months after surgery) in the high-VEGF than in the low-VEGF group (p = 0.02, unpaired t test).
CONCLUSION: Current findings indicate that careful observation is needed in patients with elevated VEGF levels.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27794575     DOI: 10.1159/000449261

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  8 in total

1.  Clinical and experimental study on angiopoietin-like protein 8 associated with proliferative diabetic retinopathy.

Authors:  Chang-Xia Dong; Cai-Ping Song; Chun-Ping Zhang; Mei Dong; Xiu-Rong Gong; He-Ying Gao; Hong Wang
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

Review 2.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

3.  Clinical Features and Vitreous Biomarkers of Early-Onset Type 2 Diabetes Mellitus Complicated with Proliferative Diabetic Retinopathy.

Authors:  DanDan Ke; YiYi Hong; XinNan Jiang; XuFang Sun
Journal:  Diabetes Metab Syndr Obes       Date:  2022-04-26       Impact factor: 3.249

4.  Proliferative diabetic retinopathy without preoperative pan-retinal photocoagulation is associated with higher levels of intravitreal IL-6 and postoperative inflammation.

Authors:  Yukihiko Suzuki; Kobu Adachi; Natsuki Maeda; Reiko Tanabu; Takashi Kudo; Mitsuru Nakazawa
Journal:  Int J Retina Vitreous       Date:  2020-06-08

5.  Change of Vascular Endothelial Growth Factor Levels following Vitrectomy in Eyes with Proliferative Diabetic Retinopathy.

Authors:  Hui-Jin Chen; Zhi-Zhong Ma; Ying Li; Chang-Guan Wang
Journal:  J Ophthalmol       Date:  2019-10-23       Impact factor: 1.909

6.  Monocyte chemoattractant protein-1 (MCP-1/CCL2) in diabetic retinopathy: latest evidence and clinical considerations.

Authors:  Yousof Taghavi; Gholamhossein Hassanshahi; Nicholas G Kounis; Ioanna Koniari; Hossein Khorramdelazad
Journal:  J Cell Commun Signal       Date:  2019-01-03       Impact factor: 5.908

Review 7.  Endothelial Dysfunction in Diabetic Retinopathy.

Authors:  Fu Gui; Zhipeng You; Shuhua Fu; Hongxi Wu; Yulan Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-04       Impact factor: 5.555

Review 8.  Intraocular fluid biomarkers (liquid biopsy) in human diabetic retinopathy.

Authors:  Edoardo Midena; Luisa Frizziero; Giulia Midena; Elisabetta Pilotto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-07-03       Impact factor: 3.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.